RenovoRx announced that the University of Nebraska Medical Center, UNMC, is now enrolling patients with Locally Advanced Pancreatic Cancer, LAPC, in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial. The TIGeR-PaC study is using RenovoRx’s patented TAMP therapy platform to evaluate its RenovoGem investigational drug-device combination product. RenovoGem utilizes pressure-mediated delivery of chemotherapy across the arterial wall to bathe tumor tissue. The study is comparing treatment with TAMP to the current standard-of-care.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx initiated with a Buy at Ascendiant
- RenovoRx appoints Ryan Witt as SVP, head of corporate strategy, partnerships
- RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
- RenovoRx Shareholders Unanimously Elect Board Directors
- RenovoRx CEO issues update letter to shareholders